Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Reuters Investment Profile
$20.00
Provider: GlobalData
$125.00
Provider: MarketLine (a Datamonitor Company)
$175.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Astellas Pharma Inc Enters License Agreement with Cubist Pharmaceuticals, Inc. to Develop and Commercialize Injectable Cephalosporin Antibiotic Cephalosporin CXA 201


Monday, 11 Mar 2013 08:00pm EDT 

Astellas Pharma Inc announced the execution of a license agreement with Cubist Pharmaceuticals, Inc., under which Cubist Pharmaceuticals has an exclusive right to develop and commercialize injectable cephalosporin antibiotic cephalosporin CXA 201 worldwide. In return for the exclusive license to develop and commercialize CXA 201 in the Territory, Astellas is entitled to receive an up-front payment of USD 25 million from Cubist Pharmaceuticals. Astellas is also eligible to receive contingent payments upon the achievement of certain development, regulatory and commercial milestones. 

Company Quote

1139.0
-1.0 -0.09%
18 Apr 2014